Benoit Roch
Benoit Roch is an expert in Oncology at University Hospital of Montpellier (France). As of October 2026, ScienceLeadR ranks Benoit Roch in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Benoit Roch has authored 53 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 13 of them ongoing. SLR score: 481 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Neurosurgery - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2016 - 2026
Number : 53
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring. PMID 42564141 — cells, lung, neoplasms, carcinoma, non-small-cell lung, biopsy, lung neoplasms, small cell lung carcinoma, diagnosis, therapeutics, liquid biopsy | Front Oncol | 2026 | 0 |
| Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial. PMID 41473840 — quality of life, safety, progression-free survival, neoplasms, carcinoma, non-small-cell lung, therapeutics | JTO Clin Res Rep | 2025 | 0 |
| Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study. PMID 40713215 — cells, lung, disease-free survival, progression-free survival, neoplasms, classification, carcinoma, non-small-cell lung, exons, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, egfr mutation | Clin Lung Cancer | 2025 | 0 |
| An Optimized Next-Generation Sequencing Method for Detecting De Novo MET Amplification in Non-Small Cell Lung Cancer: Prognostic and Therapeutic Implications. PMID 39986540 — cells, high-throughput nucleotide sequencing, lung, neoplasms, pathology, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Lab Invest | 2025 | 0 |
| What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?-A Review of Implications for Diagnosis and Treatment. PMID 39123401 — cells, lung, lymph nodes, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, lymph, small cell lung carcinoma, diagnosis, therapeutics | Cancers (Basel) | 2024 | 1 |
Clinical Studies 17
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Personnalized Immunotherapy in Patients With Stage III Non small Cell Lung Cancer NCT07759492 — cells, lung, neoplasms, carcinoma, non-small-cell lung, prescriptions, immunotherapy, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics | Phase 2 | Not yet recruiting | 2026 |
| A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer 2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics | Phase 3 | Not yet recruiting | 2026 |
| A multicentre Phase II single arm interventional study of neoadjuvant durvalumab and platinum based chemotherapy (CT) followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab in participants with resectable or borderline resectable stage IIB IIIB Nonsmall Cell Lung Cancer (NSCLC) 2023-503357-35-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, chemotherapy | Phase 2 | Active not recruiting | 2024 |
| Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II IIIA IIIB NSCLC 2023-504923-20-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, rna, messenger, lung neoplasms, small cell lung carcinoma | Phase 3 | Active not recruiting | 2024 |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated KRAS G12C Mutated Advanced or Metastatic Non Squamous Non Small Cell Lung Cancer 2024-518365-10-00 — cells, pemetrexed, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, carboplatin | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map